Literature DB >> 2463310

The human B lymphocyte and carcinoma antigen, CDw40, is a phosphoprotein involved in growth signal transduction.

S Paulie1, A Rosén, B Ehlin-Henriksson, S Braesch-Andersen, E Jakobson, H Koho, P Perlmann.   

Abstract

The human B lymphocyte and carcinoma-associated Ag, CDw40, (p50, Bp50) is a receptor candidate for normal growth regulation. Interaction of mAb with this pan-B Ag, together with preactivating agents such as 12-O-tetradecanoylphorbol-13-acetate or anti-mu, deliver strong growth-promoting signals to the cells. We here demonstrate that signaling through this Ag is dependent on its aggregation on the cell surface. Thus, monovalent antibody fragments were relatively inefficient in this respect but effectively blocked stimulation by intact antibody. By using affinity purified CDw40 protein we have also demonstrated that it is antigenically distinct from other B cell-associated Ag, including the six differentiation clusters CD19 to CD24. The mAb S2C6 and G28.5, prepared by immunizing mice with human bladder carcinoma cells or tonsillar B-cells, respectively, were the only antibodies giving detectable binding. Either of these antibodies could also completely block the binding of the other, suggesting an identity or structural proximity of the epitopes recognized. The CDw40 Ag was shown to be a phosphoprotein lacking intrinsic protein kinase activity. The results provide further evidence for CDw40 being an important B cell growth factor receptor which may also have growth regulatory functions in the development of certain human carcinomas.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2463310

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

Review 1.  Surface molecules involved in B lymphocyte function.

Authors:  P Möller; A Eichelmann; G Moldenhauer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

2.  CD antigens as promising tools for the functional analysis of solid tumours.

Authors:  P Möller
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

3.  Effect of B-cell receptor engagement on CD40-stimulated B cells.

Authors:  B M Schilizzi; R Boonstra; T H The; L F de Leij
Journal:  Immunology       Date:  1997-11       Impact factor: 7.397

4.  Inhibition of LFA-1-dependent human B-cell aggregation induced by CD40 antibodies and interleukin-4 leads to decreased IgE synthesis.

Authors:  P Björck; S Paulie
Journal:  Immunology       Date:  1993-02       Impact factor: 7.397

5.  CD40 plays an essential role in the activation of human B cells by murine EL4B5 cells.

Authors:  J Kwekkeboom; M De Boer; J M Tager; C De Groot
Journal:  Immunology       Date:  1993-07       Impact factor: 7.397

6.  Anti-CD40 antibody stimulates the VLA-4-dependent adhesion of normal and LFA-1-deficient B cells to endothelium.

Authors:  L Flores-Romo; D Estoppey; K B Bacon
Journal:  Immunology       Date:  1993-07       Impact factor: 7.397

Review 7.  The CD40, CTLA-4, thyroglobulin, TSH receptor, and PTPN22 gene quintet and its contribution to thyroid autoimmunity: back to the future.

Authors:  Eric M Jacobson; Yaron Tomer
Journal:  J Autoimmun       Date:  2007-03-21       Impact factor: 7.094

8.  Antibodies to distinct epitopes on the CD40 molecule co-operate in stimulation and can be used for the detection of soluble CD40.

Authors:  P Björck; S Braesch-Andersen; S Paulie
Journal:  Immunology       Date:  1994-11       Impact factor: 7.397

9.  The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity.

Authors:  D Hollenbaugh; L S Grosmaire; C D Kullas; N J Chalupny; S Braesch-Andersen; R J Noelle; I Stamenkovic; J A Ledbetter; A Aruffo
Journal:  EMBO J       Date:  1992-12       Impact factor: 11.598

10.  CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40.

Authors:  M R Alderson; R J Armitage; T W Tough; L Strockbine; W C Fanslow; M K Spriggs
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.